Intravenous and subcutaneous insulin combined with omega-3 fatty acids effectively and safely reduced triglyceride levels below 1000 mg/dL in a 2-month-old infant with LPL deficiency.
Case Report (n=1)
No
Does insulin therapy and omega-3 fatty acid adjustment reduce triglyceride levels in an infant with severe hypertriglyceridemia due to LPL deficiency?
Insulin therapy combined with omega-3 fatty acids successfully managed severe hypertriglyceridemia in an infant with LPL deficiency.
This case describes the individualised pharmacological management of a 2-month-old infant with genetically confirmed type I hypertriglyceridemia due to lipoprotein lipase (LPL) deficiency. After the failure of conventional treatment and contraindication to plasmapheresis, intravenous insulin therapy was initiated, followed by subcutaneous insulin and omega-3 fatty acid adjustment. The hospital pharmacist played a key role in selecting off-label treatments, adapting pharmaceutical forms for paediatric use and performing therapeutic reconciliation. The approach was effective and safe, achieving triglyceride levels below 1000 mg/dL and clinical stability. This report contributes practical evidence on alternative treatment strategies for a rare disease with limited therapeutic options in paediatrics, highlighting the importance of a multidisciplinary approach and pharmaceutical care.
Pardo et al. (Wed,) conducted a case report in Severe hypertriglyceridemia due to lipoprotein lipase deficiency (n=1). Intravenous insulin therapy followed by subcutaneous insulin and omega-3 fatty acids was evaluated on Triglyceride levels. Intravenous and subcutaneous insulin combined with omega-3 fatty acids effectively and safely reduced triglyceride levels below 1000 mg/dL in a 2-month-old infant with LPL deficiency.